Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients

Primary objectives: Biomarker evaluation under antiannagiogenic therapy with Nexavar, Sutent and Avastin. Eligible patients are suffering from hepatocellular carcinoma, non small cell lung cancer, renal cell cancer and colorectal cancer routinely treated with the abov mentioned antiangiogenic agents.
Primary endpoints: Evaluation of biomarker analyses